Chapter 7.2
Pathogenesis of Portal Hypertension
Roberto J. Groszmann,
Juan G. Abraldes,
Roberto J. Groszmann
Search for more papers by this authorJuan G. Abraldes
Search for more papers by this authorRoberto J. Groszmann,
Juan G. Abraldes,
Roberto J. Groszmann
Search for more papers by this authorJuan G. Abraldes
Search for more papers by this authorBook Editor(s):Juan Rodés MD,
Jean-Pierre Benhamou MD,
Andres T. Blei MD,
Jürg Reichen MD,
Mario Rizzetto MD,
Juan Rodés MD
Director General, Hospital Clinic; Professor of Medicine, University of Barcelona, Barcelona, Spain
Search for more papers by this authorJean-Pierre Benhamou MD
Professor of Hepatology, Université Denis Diderot Paris 7, Assistance Publique — Hôpitaux de Paris and Inserm U773, Service d'Hépatologie, Hôpital Beaujon, Clichy, France
Search for more papers by this authorAndres T. Blei MD
Professor of Medicine and Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorJürg Reichen MD
Professor of Medicine, University of Bern; Chief of Hepatology, University Hospital, Bern, Switzerland
Search for more papers by this authorMario Rizzetto MD
Professor of Gastroenterology, University of Turin, Turin, Italy
Search for more papers by this authorFirst published: 18 June 2007
References
- Sikuler E, Groszmann RJ (1986) Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am J Physiol 250, G205–G212.
- Wanless IR, Wong F, Blendis LM et al. (1995) Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 21, 1238–1247.
- Bhathal PS, Grossman HJ (1985) Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1, 325–337.
-
Zhang JX,
Pegoli W Jr,
Clemens MG
(1994)
Endothelin-1 induces direct constriction of hepatic sinusoids.
Am J Physiol (Gastrointest Liver Physiol)
29,
G624–G632.
10.1152/ajpgi.1994.266.4.G624 Google Scholar
- Pinzani M, Gentilini P (1999) Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 19, 397–410.
- Kaneda K, Sogawa M, Matsumara A et al. (1998) Endothelin-1 induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology 27, 735–747.
- Loureiro-Silva MR, Cadelina GW, Groszmann RJ (2003) Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am J Physiol Gastrointest Liver Physiol 284, G567–G574.
- Mittal MK, Gupta TK, Lee FY et al. (1994) Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol 267, G416–G422.
- Gupta TK, Toruner M, Chung MK et al. (1998) Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28, 926–931.
- Rockey DC, Chung JJ (1998) Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 114, 344–351.
- Shah V, Toruner M, Haddad F et al. (1999) Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 117, 1222–1228.
- Bellis L, Berzigotti A, Abraldes JG et al. (2003) Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 37, 378–384.
- Van de CM, Omasta A, Janssens S et al. (2002) In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 51, 440–445.
- Loureiro-Silva MR, Cadelina GW, Iwakiri Y et al. (2003) A liver-specific nitric oxide donor improves the intrahepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol 39, 940–946.
- Morales-Ruiz M, Cejudo-Martn P, Fernandez-Varo G et al. (2003) Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 125, 522–531.
- Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW et al. (2002) Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology 36, 381–385.
- Van De Casteele M, Van Pelt JF, Nevens F et al. (2003) Low NO bioavailability in CCl4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: a comparison of two portal hypertensive rat models with healthy controls. Comp Hepatol 2, 2.
- Loureiro-Silva MR, Iwakiri Y, Abraldes JG et al. (2006) Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. J Hepatol 44, 886–893.
- Suematsu M, Goda N, Sano T et al. (1995) Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 96, 2431–2437.
- Makino N, Suematsu M, Sugiura Y et al. (2001) Altered expression of heme oxygenase-1 in the livers of patients with portal hypertensive diseases. Hepatology 33, 32–42.
- Ballet F, Chretien Y, Rey C et al. (1988) Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther 244, 233–235.
- Rockey DC, Weisiger RA (1996) Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 24, 233–240.
- Graupera M, Garcia-Pagan JC, Abraldes JG et al. (2003) Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 37, 172–181.
- Titos E, Claria J, Bataller R et al. (2000) Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 119, 794–805.
- Pinzani M, Milani S, De Franco R et al. (1996) Endothelin 1 is overex-pressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 110, 534–548.
- Bosch J, Arroyo V, Betriu A et al. (1980) Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 78, 92–99.
- Graupera M, Garcia-Pagan JC, Titos E et al. (2002) 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology 122, 387–393.
- Asbert M, Gines A, Gines P et al. (1993) Circulating levels of end-othelin in cirrhosis. Gastroenterology 104, 1485–1491.
- Elliot AJ, Vo LT, Grossman VL et al. (1997) Endothelin-induced vasoconstriction in isolated perfused liver preparations from normal and cirrhotic rats. J Gastroenterol Hepatol 12, 314–318.
- Bosch J, Abraldes JG, Groszmann RJ (2003) Current management of portal hypertension. J Hepatol 38, S54–S68.
- Tripathi D, Therapondos G, Ferguson JW et al. (2006) Endothelin-1 contributes to the maintenance of systemic but not portal haemody-namics in patients with early cirrhosis: a randomised controlled trial. Gut 55, 1290–1295.
- Bataller R, Gines P, Nicolas JM et al. (2000) Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118, 1149–1156.
- Bataller R, Sancho-Bru P, Gines P et al. (2003) Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 125, 117–125.
- Schrier RW, Arroyo V, Bernardi M et al. (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8, 1151–1157.
- Gonzalez-Abraldes J, Albillos A, Banares R et al. (2001) Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 121, 382–388.
- Graupera M, March S, Engel P et al. (2005) Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. Am J Physiol Gastrointest Liver Physiol 288, G763–G770.
- Fernandez M, Vizzutti F, Garcia-Pagan JC et al. (2004) Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126, 886–894.
- Sieber CC, Sumanovski LT, Stumm M et al. (2001) In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol 34, 644–650.
- Mosca P, Lee FY, Kaumann AJ et al. (1992) Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am J Physiol 263, G544–G550.
- Chan CC, Wang SS, Lee FY et al. (2001) Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 33, 816–820.
- Kotelanski B, Groszmann R, Cohn JN (1972) Circulation times in the splanchnic and hepatic beds in alcoholic liver disease. Gastroenterology 63, 102–111.
- Vorobioff J, Bredfeldt J, Groszmann RJ et al. (1983) Hyperdynamic circulation in a portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 244, G52–G56.
- Groszmann RJ (1994) Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 20, 1359–1363.
- Iwakiri Y, Groszmann RJ (2006) The hyperdynamic circulation in chronic liver diseases: from the Patient to the Molecule. Hepatology 43 (2 Suppl. 1), S121–131.
- Gomis R, Fernandez-Alvarez J, Pizcueta P et al. (1994) Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation. Hepatology 19, 1257–1261.
- Kravetz D, Bosch J, Arderiu MT et al. (1988) Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 254, G322–G328.
- Albillos A, Rossi I, Iborra J et al. (1994) Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 21, 88–94.
- Wiest R, Tsai MH, Groszmann RJ (2001) Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology 120, 975–983.
- Batkai S, Jarai Z, Wagner JA et al. (2001) Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Med 7, 827–832.
- Ros J, Claria J, To-Figueras J et al. (2002) Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122, 85–93.
- Vallance P, Moncada S (1991) Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 337, 776.
- Guarner C, Soriano G, Tomas A et al. (1993) Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotox-emia. Hepatology 18, 1139–1143.
- Hori N, Wiest R, Groszmann RJ (1998) Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology 28, 1467–1473.
- Lee FY, Colombato LA, Albillos A et al. (1993) Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 105, 1464–1470.
- García-Pagán JC, Fernandez M, Bernadich C et al. (1994) Effects of continued nitric oxide inhibition on the development of the portal hypertensive syndrome following portal vein stenosis in the rat. Am J Physiol 30, 984–990.
- Iwakiri Y, Cadelina G, Sessa WC et al. (2002) Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 283, G1074–G1081.
- Wiest R, Groszmann RJ (2002) The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35, 478–491.
- Jurzik L, Froh M, Straub RH et al. (2005) Up-regulation of nNOS and associated increase in nitrergic vasodilation in superior mesenteric arteries in pre-hepatic portal hypertension. J Hepatol 43, 258–265.
- Kwon SY, Groszmann RJ, Iwakiri Y (2007) Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats. Hepatol Res (in press).
- Wiest R, Das S, Cadelina G et al. (1999) Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 104, 1223–1233.
- Bernadich C, Bandi JC, Piera C et al. (1997) Circulatory effects of graded diversion of portal blood flow to the systemic circulation in rats: role of nitric oxide. Hepatology 26, 262–267.
- Wiest R, Shah V, Sessa WC et al. (1999) NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 276, G1043–G1051.
- Tsai MH, Iwakiri Y, Cadelina G et al. (2003) Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 125, 1452–1461.
- Abraldes JG, Iwakiri Y, Loureiro-Silva Y et al. (2006) Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 290, G980–G987.
- Fernandez M, Mejias M, Angermayr B et al. (2005) Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 43, 98–103.
- Iwakiri Y, Tsai MH, McCabe TJ et al. (2002) Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol 282, H2084–H2090.
- Shah V, Wiest R, Garcia-Cardena G et al. (1999) Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol 277 G463–G468.
- Wiest R, Cadelina G, Milstien S et al. (2003) Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 38, 1508–1515.
- Guarner C, Soriano G, Such J et al. (1992) Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 102, 303–309.
- Sitzmann JV, Bulkley GB (1989) Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann Surg 209, 322–327.
- Potenza MA, Botrugno OA, De Salvia MA et al. (2002) Endothelial COX-1 and -2 differentially affect reactivity of MVB in portal hypertensive rats. Am J Physiol Gastrointest Liver Physiol 283, G587–G594.
- Fernandez M, Garcia-Pagan JC, Casadevall M et al. (1996) Acute and chronic cyclooxygenase blockade in portal hypertensive rats. Influence on nitric oxide biosynthesis. Gastroenterology 110, 1529–1535.
- Bruix J, Bosch J, Kravetz D et al. (1985) Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 88, 430–435.
- Genecin P, Polio J, Groszmann RJ (1990) Na restriction blunts expansion of plasma volume and ameliorates hyperdynamic circulation in portal hypertension. Am J Physiol 259, G498–G503.
- Garcia-Pagan JC, Salmeron JM, Feu F et al. (1994) Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 19, 1095–1099.
- Albillos A, Colombato LA, Groszmann RJ (1992) Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 102, 931–935.
- Colombato LA, Albillos A, Groszmann RJ (1996) The role of central blood volume in the development of sodium retention in portal hypertensive rats. Gastroenterology 110, 193–198.
